CClinicalTrials.gg
CompletedNCT05743348TELECOVIDUpdated Feb 24, 2023

COVID-19 e Telepsychotherapy: Which Variables Affect Therapeutic Experience?

An observational study in Telepsychotherapy, sponsored by Istituto Auxologico Italiano. Completed at 1 site in Italy. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-24.

Sponsored by Istituto Auxologico Italiano · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
71
Ages
18 Years to 100 Years
Sex
All
01

Study summary

COVID-19 pandemic forced a widespread adoption of telemedicine, including telepsychotherapy.

Telepsychotherapy has been proven to be effective before COVID-19 breakout (Poletti et al., 2020); however, both patients and therapists were skeptical about this modality.

The aim of this study is to probe the experience of telepsychotherapy in both patients and therapists, during the COVID-19 lockdown. Thus, when the adoption of online colloquia was mandatory and not an option.

Crucially, studying the experience of telepsychotherapy during the COVID-19 pandemic allows i) investigating also the experience of those patients and therapists that were not favorable to this kind of intervention and ii) comparing the experience of therapy in the online and face-to-face modality, in the same patients and therapists. Furthermore, we collect several psychological variables that possibly influence the experience and efficacy of telepsychotherapy (e.g., personality traits, attachment state of mind, previous traumatic experiences) to define the psychological profile behind a favorable or negative experience of telemedicine in both patients and therapists. As crucial novelty, this information is collected in both patients and their therapists, allowing the direct comparisons between the experience of the therapeutic relationship (e.g., empathy, alliance) from two different point of views.

The results of the present study may help in the definition of possible subgroups of patients who may be sufficiently responsive to telepsychotherapy and those who may benefit - exclusively - of face-to-face interventions.

02

Conditions studied

  • Telepsychotherapy
03

In context

Lead sponsor

Istituto Auxologico Italiano is the lead sponsor of 196 studies on the registry; 78 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study addresses both licensed and currently practicing psychotherapists and their patients, namely individuals currently undergoing a psychotherapy

Inclusion criteria

  • Licensed and currently practicing psychotherapists
  • Individuals currently undergoing a psychotherapy

Exclusion criteria

Exclusion Criteria:

  • not applicable
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
71 participants (actual)
Patient registry
No

Interventions

  • BehavioralTelepsychotherapy

    Remotely delivered psychotherapy sessions

06

What researchers measure

Primary outcomes

  1. Telepsychotherapy perception

    Psychometric measures of general perception/experience on the remotely delivered psychotherapy as far as efficacy and interpersonal factors are concerned

    Time frame: At enrollment

07

Study locations

1 site
  • Istituto Auxologico Italiano
    Milan, 20149, Italy
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05743348
Lead sponsor
Istituto Auxologico Italiano
Responsible party
Sponsor
First posted
Feb 24, 2023
Start date
Apr 5, 2021
Primary completion
Apr 30, 2022
Completion
Apr 30, 2022
Last update
Feb 24, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion